Monographie - Mycophenolate mofetil

Letztes “update” :
19/11/2024

Mycophenolate mofetil

Chemische Struktur

Handelsmarke

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Cellcept	Australien, Dänemark, Deutschland, Finnland, Frankreich, Griechenland, Großbritannien, Irland, Italien, Japan, Kanada, Kolumbien, Luxemburg, Mexiko, Neuseeland, Niederlande, Norwegen, Österreich, Polen, Portugal, Schweden, Schweiz, Spanien, Ungarn, Vereinigte Staaten von Amerika
Micofenolato de mofetilo	Spanien
Mycophenolate mofetil	Belgien, Deutschland, Großbritannien

Literaturverzeichnis : Mycophenolate mofetil

	Typ	Veröffentlichung
1981	Zeitung	Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C. Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags. Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982	Zeitung	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	Zeitung	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2192	Zeitung	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247	Zeitung	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728	Zeitung	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Zeitung	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299	Zeitung	Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M. Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device. Biomed Chromatogr 2019 ; 33, 7: e4529.
4528	Zeitung	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4698	Zeitung	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022

Mentions Légales